Navigation Links
Eurand Added to NASDAQ Biotechnology Index
Date:11/12/2007

AMSTERDAM, Netherlands, Nov. 12 /PRNewswire-FirstCall/ -- Eurand N.V. (Nasdaq: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), effective November 19, 2007.

Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We are delighted to be included in this important NASDAQ index and believe it is further validation of our position in the life sciences industry."

The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies that meet eligibility criteria including market capitalization minimums, trading volume minimums, and ICB classification. The index is ranked on a semi-annual basis in May and November. More information about the NBI is available at http://www.nasdaq.com

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and filed a rolling NDA for this product which the company anticipates to complete by the end of 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at http://www.eurand.com.

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

Contacts:

Mario Crovetto Nick Laudico/Elizabeth Scott

Chief Financial Officer The Ruth Group

Eurand N.V. 646-536-7030/7014

+39 02 95428 521 nlaudico@theruthgroup.com

mario.crovetto@eurand.com escott@theruthgroup.com


'/>"/>
SOURCE Eurand N.V.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
6. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
7. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
8. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 18, 2017 Kurzlehrgang mit ... adoptiven Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei ... ... wird Dr. Yoav Peretz , Scientific Director bei ... von Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien ...
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting ... be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). ... provide an opportunity to interact with peers, make new connections and talk bio biz. ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
Breaking Biology News(10 mins):